Viking's Obesity Drug VANQUISH Fully Enrolled; Oral Phase III Set for Q4
VKTX sits 42% above its 52-week low of $22.959.
Summary
Viking Therapeutics completed enrollment in its pivotal Phase III VANQUISH subcutaneous obesity trials, with VANQUISH-1 enrolling ~4,500 patients and VANQUISH-2 ~1,000. The company also announced plans to start an oral Phase III program in Q4 2026, expanding its obesity pipeline. This follows last week's Q2 report showing a $502 million cash position and a new $500 million ATM shelf, providing ample funding for these late-stage programs. Canaccord raised its price target to $114 from $107, reflecting increased confidence in the obesity franchise. Full enrollment de-risks the subcutaneous program and sets up a data readout that could transform Viking's commercial prospects. The oral program adds a second, potentially larger market opportunity. With cash runway secured, the focus now shifts to trial execution and eventual data.
At the time of this announcement, VKTX was trading at $32.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $22.96 to $43.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.